Momenta Pharmaceuticals Inc. (MNTA)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.00-0.33 (-2.68%)
At close: 4:00 PM EDT
People also watch:
ALNYACORNBIXTHRXMDCO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open12.39
Prev Close12.33
Bid0.00 x
Ask14.49 x 200
Day's Range11.88 - 12.39
52wk Range7.86 - 20.58
1y Target EstN/A
Market Cap848.88M
P/E Ratio (ttm)-7.86
Beta1.80
Volume382,310
Avg Vol (3m)462,598
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube9 days ago

    ETF’s with exposure to Momenta Pharmaceuticals, Inc. : August 15, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Momenta Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to MNTA-US. Comparing the performance and risk of Momenta Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
    Capital Cube12 days ago

    Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016

    Categories: Yahoo Finance Click here to see latest analysis Momenta Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Momenta Pharmaceuticals, Inc. – Biogen Inc., Baxter International Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Limited Sponsored ADR, Amgen Inc., Pfizer Inc., Novartis AG Sponsored ADR, ... Read more (Read more...)

  • Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
    Zacks12 days ago

    Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat

    Earnings remained in focus with several companies including Regeneron (REGN) reporting second quarter results.